{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:50:12Z","timestamp":1793235012653,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP23K07824"],"award-info":[{"award-number":["JP23K07824"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP24H00866"],"award-info":[{"award-number":["JP24H00866"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP24ama221135"],"award-info":[{"award-number":["JP24ama221135"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP23ama221126"],"award-info":[{"award-number":["JP23ama221126"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008886","name":"Princess Takamatsu Cancer Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008886","id-type":"DOI","asserted-by":"publisher"}]},{"name":"JST CREST","award":["JPMJCR23B7"],"award-info":[{"award-number":["JPMJCR23B7"]}]},{"DOI":"10.13039\/100017682","name":"Japanese Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017682","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ono Pharmaceutical Foundation for Oncology"},{"DOI":"10.13039\/501100004398","name":"Mitsubishi Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004398","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007533","name":"Kobayashi Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007533","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chugai Foundation for Innovative Drug Discovery Science"},{"DOI":"10.13039\/501100006062","name":"Foundation for Promotion of Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-21034-1","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T11:44:59Z","timestamp":1761219899000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["BRD4 and MYB inhibition overcomes venetoclax resistance in EVI1-rearranged acute myeloid leukemia"],"prefix":"10.1038","volume":"15","author":[{"given":"Weijia","family":"Zang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yui","family":"Koike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koutarou","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaya","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Aoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Saika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muran","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyoshi","family":"Kunimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akifumi","family":"Takaori-Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daichi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"21034_CR1","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/modpathol.2010.210","volume":"24","author":"J Sun","year":"2011","unstructured":"Sun, J. et al. De Novo acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): A clinicopathologic and cytogenetic study of an entity recently added to the WHO classification. Mod. Pathol. 24, 384\u2013389. https:\/\/doi.org\/10.1038\/modpathol.2010.210 (2011).","journal-title":"Mod. Pathol."},{"key":"21034_CR2","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.1200\/JCO.2010.29.2771","volume":"28","author":"S Lugthart","year":"2010","unstructured":"Lugthart, S. et al. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)\/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J. Clin. Oncol. 28, 3890\u20133898. https:\/\/doi.org\/10.1200\/JCO.2010.29.2771 (2010).","journal-title":"J. Clin. Oncol."},{"key":"21034_CR3","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1309\/AJCP48AJDCKTHUXC","volume":"136","author":"W Cui","year":"2011","unstructured":"Cui, W., Sun, J., Cotta, C. V., Medeiros, L. J. & Lin, P. Myelodysplastic syndrome with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) has a high risk for progression to acute myeloid leukemia. Am. J. Clin. Pathol. 136, 282\u2013288. https:\/\/doi.org\/10.1309\/AJCP48AJDCKTHUXC (2011).","journal-title":"Am. J. Clin. Pathol."},{"key":"21034_CR4","doi-asserted-by":"publisher","first-page":"821","DOI":"10.3324\/haematol.2013.096420","volume":"99","author":"HJ Rogers","year":"2014","unstructured":"Rogers, H. J. et al. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)\/t(3;3)(q21;q26.2): A bone marrow pathology group study. Haematologica 99, 821\u2013829. https:\/\/doi.org\/10.3324\/haematol.2013.096420 (2014).","journal-title":"Haematologica"},{"key":"21034_CR5","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1200\/JCO.2009.26.0646","volume":"28","author":"S Groschel","year":"2010","unstructured":"Groschel, S. et al. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J. Clin. Oncol. 28, 2101\u20132107. https:\/\/doi.org\/10.1200\/JCO.2009.26.0646 (2010).","journal-title":"J. Clin. Oncol."},{"key":"21034_CR6","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1080\/10428194.2020.1737689","volume":"61","author":"I Summerer","year":"2020","unstructured":"Summerer, I. et al. Prognosis of MECOM (EVI1)-rearranged MDS and AML patients rather depends on accompanying molecular mutations than on blast count. Leuk. Lymphoma. 61, 1756\u20131759. https:\/\/doi.org\/10.1080\/10428194.2020.1737689 (2020).","journal-title":"Leuk. Lymphoma"},{"key":"21034_CR7","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ccr.2014.02.008","volume":"25","author":"H Yamazaki","year":"2014","unstructured":"Yamazaki, H. et al. A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression. Cancer Cell. 25, 415\u2013427. https:\/\/doi.org\/10.1016\/j.ccr.2014.02.008 (2014).","journal-title":"Cancer Cell."},{"key":"21034_CR8","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.cell.2014.02.019","volume":"157","author":"S Groschel","year":"2014","unstructured":"Groschel, S. et al. A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. Cell 157, 369\u2013381. https:\/\/doi.org\/10.1016\/j.cell.2014.02.019 (2014).","journal-title":"Cell"},{"key":"21034_CR9","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1128\/mcb.11.5.2665-2674.1991","volume":"11","author":"AS Perkins","year":"1991","unstructured":"Perkins, A. S., Fishel, R., Jenkins, N. A. & Copeland, N. G. Evi-1, a murine zinc finger proto-oncogene, encodes a sequence-specific DNA-binding protein. Mol. Cell. Biol. 11, 2665\u20132674. https:\/\/doi.org\/10.1128\/mcb.11.5.2665-2674.1991 (1991).","journal-title":"Mol. Cell. Biol."},{"key":"21034_CR10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41408-021-00457-9","volume":"11","author":"C Birdwell","year":"2021","unstructured":"Birdwell, C. et al. EVI1 dysregulation: Impact on biology and therapy of myeloid malignancies. Blood Cancer J. 11, 64. https:\/\/doi.org\/10.1038\/s41408-021-00457-9 (2021).","journal-title":"Blood Cancer J."},{"key":"21034_CR11","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1182\/blood.2021015325","volume":"140","author":"A Tanaka","year":"2022","unstructured":"Tanaka, A. et al. Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia. Blood 140, 875\u2013888. https:\/\/doi.org\/10.1182\/blood.2021015325 (2022).","journal-title":"Blood"},{"key":"21034_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo, C. D. et al. Venetoclax combined with decitabine or Azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133, 7\u201317. https:\/\/doi.org\/10.1182\/blood-2018-08-868752 (2019).","journal-title":"Blood"},{"key":"21034_CR13","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ccr.2006.03.027","volume":"9","author":"M Certo","year":"2006","unstructured":"Certo, M. et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 9, 351\u2013365. https:\/\/doi.org\/10.1016\/j.ccr.2006.03.027 (2006).","journal-title":"Cancer Cell."},{"key":"21034_CR14","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers, A. J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19, 202\u2013208. https:\/\/doi.org\/10.1038\/nm.3048 (2013).","journal-title":"Nat. Med."},{"key":"21034_CR15","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo, C. D. et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl. J. Med. 383, 617\u2013629. https:\/\/doi.org\/10.1056\/NEJMoa2012971 (2020).","journal-title":"N Engl. J. Med."},{"key":"21034_CR16","doi-asserted-by":"publisher","first-page":"e830","DOI":"10.1016\/S2352-3026(24)00241-2","volume":"11","author":"D Russo","year":"2024","unstructured":"Russo, D. et al. Venetoclax plus decitabine as a Bridge to allogeneic Haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): Final report of a multicentre, single-arm, phase 2 trial. Lancet Haematol. 11, e830\u2013e838. https:\/\/doi.org\/10.1016\/S2352-3026(24)00241-2 (2024).","journal-title":"Lancet Haematol."},{"key":"21034_CR17","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1182\/blood.V84.4.1243.1243","volume":"84","author":"M Russell","year":"1994","unstructured":"Russell, M. et al. Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations. Blood 84, 1243\u20131248 (1994).","journal-title":"Blood"},{"key":"21034_CR18","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1182\/blood-2014-07-591461","volume":"125","author":"S Groschel","year":"2015","unstructured":"Groschel, S. et al. Mutational spectrum of myeloid malignancies with inv(3)\/t(3;3) reveals a predominant involvement of RAS\/RTK signaling pathways. Blood 125, 133\u2013139. https:\/\/doi.org\/10.1182\/blood-2014-07-591461 (2015).","journal-title":"Blood"},{"key":"21034_CR19","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1182\/blood-2014-07-591529","volume":"125","author":"VP Lavallee","year":"2015","unstructured":"Lavallee, V. P. et al. EVI1-rearranged acute myeloid leukemias are characterized by distinct molecular alterations. Blood 125, 140\u2013143. https:\/\/doi.org\/10.1182\/blood-2014-07-591529 (2015).","journal-title":"Blood"},{"key":"21034_CR20","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","volume":"562","author":"JW Tyner","year":"2018","unstructured":"Tyner, J. W. et al. Functional genomic landscape of acute myeloid leukaemia. Nature 562, 526\u2013531. https:\/\/doi.org\/10.1038\/s41586-018-0623-z (2018).","journal-title":"Nature"},{"key":"21034_CR21","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","volume":"40","author":"D Bottomly","year":"2022","unstructured":"Bottomly, D. et al. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell 40, 850\u2013864 e859, (2022). https:\/\/doi.org\/10.1016\/j.ccell.2022.07.002","journal-title":"Cancer Cell"},{"key":"21034_CR22","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.ccell.2016.08.006","volume":"30","author":"EA Obeng","year":"2016","unstructured":"Obeng, E. A. et al. Physiologic expression of Sf3b1(K700E) causes impaired erythropoiesis, aberrant splicing, and sensitivity to therapeutic spliceosome modulation. Cancer Cell. 30, 404\u2013417. https:\/\/doi.org\/10.1016\/j.ccell.2016.08.006 (2016).","journal-title":"Cancer Cell."},{"key":"21034_CR23","doi-asserted-by":"publisher","first-page":"6232","DOI":"10.1073\/pnas.85.17.6232","volume":"85","author":"M Cross","year":"1988","unstructured":"Cross, M., Mangelsdorf, I., Wedel, A. & Renkawitz, R. Mouse lysozyme M gene: Isolation, characterization, and expression studies. Proc. Natl. Acad. Sci. U S A. 85, 6232\u20136236. https:\/\/doi.org\/10.1073\/pnas.85.17.6232 (1988).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"21034_CR24","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/386181a0","volume":"386","author":"A Kharitonenkov","year":"1997","unstructured":"Kharitonenkov, A. et al. A family of proteins that inhibit signalling through tyrosine kinase receptors. Nature 386, 181\u2013186. https:\/\/doi.org\/10.1038\/386181a0 (1997).","journal-title":"Nature"},{"key":"21034_CR25","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1073\/pnas.94.2.569","volume":"94","author":"DE Zhang","year":"1997","unstructured":"Zhang, D. E. et al. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc. Natl. Acad. Sci. U S A. 94, 569\u2013574. https:\/\/doi.org\/10.1073\/pnas.94.2.569 (1997).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"21034_CR26","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1084\/jem.189.11.1847","volume":"189","author":"JA Lekstrom-Himes","year":"1999","unstructured":"Lekstrom-Himes, J. A., Dorman, S. E., Kopar, P., Holland, S. M. & Gallin, J. I. Neutrophil-specific granule deficiency results from a novel mutation with loss of function of the transcription factor CCAAT\/enhancer binding protein epsilon. J. Exp. Med. 189, 1847\u20131852. https:\/\/doi.org\/10.1084\/jem.189.11.1847 (1999).","journal-title":"J. Exp. Med."},{"key":"21034_CR27","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/ng1366","volume":"36","author":"FW Buaas","year":"2004","unstructured":"Buaas, F. W. et al. Plzf is required in adult male germ cells for stem cell self-renewal. Nat. Genet. 36, 647\u2013652. https:\/\/doi.org\/10.1038\/ng1366 (2004).","journal-title":"Nat. Genet."},{"key":"21034_CR28","doi-asserted-by":"publisher","first-page":"111759","DOI":"10.1016\/j.celrep.2022.111759","volume":"41","author":"JS Lee","year":"2022","unstructured":"Lee, J. S. et al. The insulin and IGF signaling pathway sustains breast cancer stem cells by IRS2\/PI3K-mediated regulation of MYC. Cell. Rep. 41, 111759. https:\/\/doi.org\/10.1016\/j.celrep.2022.111759 (2022).","journal-title":"Cell. Rep."},{"key":"21034_CR29","first-page":"2168","volume":"7","author":"MA Shah","year":"2001","unstructured":"Shah, M. A. & Schwartz, G. K. Cell cycle-mediated drug resistance: An emerging concept in cancer therapy. Clin. Cancer Res. 7, 2168\u20132181 (2001).","journal-title":"Clin. Cancer Res."},{"key":"21034_CR30","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature09504","volume":"468","author":"P Filippakopoulos","year":"2010","unstructured":"Filippakopoulos, P. et al. Selective Inhibition of BET bromodomains. Nature 468, 1067\u20131073. https:\/\/doi.org\/10.1038\/nature09504 (2010).","journal-title":"Nature"},{"key":"21034_CR31","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41586-020-1930-8","volume":"578","author":"EJ Faivre","year":"2020","unstructured":"Faivre, E. J. et al. Selective Inhibition of the BD2 bromodomain of BET proteins in prostate cancer. Nature 578, 306\u2013310. https:\/\/doi.org\/10.1038\/s41586-020-1930-8 (2020).","journal-title":"Nature"},{"key":"21034_CR32","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1182\/blood-2015-09-668632","volume":"127","author":"S Uttarkar","year":"2016","unstructured":"Uttarkar, S. et al. Targeting acute myeloid leukemia with a small molecule inhibitor of the Myb\/p300 interaction. Blood 127, 1173\u20131182. https:\/\/doi.org\/10.1182\/blood-2015-09-668632 (2016).","journal-title":"Blood"},{"key":"21034_CR33","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.canlet.2020.01.039","volume":"479","author":"MV Yusenko","year":"2020","unstructured":"Yusenko, M. V. et al. Monensin, a novel potent MYB inhibitor, suppresses proliferation of acute myeloid leukemia and adenoid cystic carcinoma cells. Cancer Lett. 479, 61\u201370. https:\/\/doi.org\/10.1016\/j.canlet.2020.01.039 (2020).","journal-title":"Cancer Lett."},{"key":"21034_CR34","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.1097\/HS9.0000000000000469","volume":"4","author":"H Kunimoto","year":"2020","unstructured":"Kunimoto, H. et al. Establishment of a high-risk MDS\/AML cell line YCU-AML1 and its xenograft model harboring t(3;3) and monosomy 7. Hemasphere 4, e469. https:\/\/doi.org\/10.1097\/HS9.0000000000000469 (2020).","journal-title":"Hemasphere"},{"key":"21034_CR35","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","volume":"20","author":"S Zheng","year":"2022","unstructured":"Zheng, S. et al. SynergyFinder plus: Toward better interpretation and annotation of drug combination screening datasets. Genomics Proteom. Bioinf. 20, 587\u2013596. https:\/\/doi.org\/10.1016\/j.gpb.2022.01.004 (2022).","journal-title":"Genomics Proteom. Bioinf."},{"key":"21034_CR36","first-page":"2113","volume":"11","author":"RG Ramsay","year":"1995","unstructured":"Ramsay, R. G. et al. Regulation of c-Myb through protein phosphorylation and leucine zipper interactions. Oncogene 11, 2113\u20132120 (1995).","journal-title":"Oncogene"},{"key":"21034_CR37","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1038\/sj.onc.1204345","volume":"20","author":"A Cures","year":"2001","unstructured":"Cures, A., House, C., Kanei-Ishii, C., Kemp, B. & Ramsay, R. G. Constitutive c-Myb amino-terminal phosphorylation and DNA binding activity uncoupled during entry and passage through the cell cycle. Oncogene 20, 1784\u20131792. https:\/\/doi.org\/10.1038\/sj.onc.1204345 (2001).","journal-title":"Oncogene"},{"key":"21034_CR38","first-page":"1233","volume":"7","author":"H Nakagoshi","year":"1992","unstructured":"Nakagoshi, H., Kanei-Ishii, C., Sawazaki, T., Mizuguchi, G. & Ishii, S. Transcriptional activation of the c-myc gene by the c-myb and B-myb gene products. Oncogene 7, 1233\u20131240 (1992).","journal-title":"Oncogene"},{"key":"21034_CR39","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/ejh.13417","volume":"105","author":"M Sitges","year":"2020","unstructured":"Sitges, M. et al. Acute myeloid leukemia with inv(3)(q21.3q26.2)\/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols. Eur. J. Haematol. 105, 138\u2013147. https:\/\/doi.org\/10.1111\/ejh.13417 (2020).","journal-title":"Eur. J. Haematol."},{"key":"21034_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16061091","author":"S Garciaz","year":"2024","unstructured":"Garciaz, S., Hospital, M. A., Collette, Y. & Vey, N. Venetoclax resistance in acute myeloid leukemia. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers16061091 (2024).","journal-title":"Cancers (Basel)"},{"key":"21034_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25063231","author":"KH Klempnauer","year":"2024","unstructured":"Klempnauer, K. H. Transcription factor MYB as therapeutic target: Current developments. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms25063231 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"21034_CR42","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1158\/2159-8290.CD-20-1793","volume":"11","author":"L Smeenk","year":"2021","unstructured":"Smeenk, L. et al. Selective requirement of MYB for oncogenic hyperactivation of a translocated enhancer in leukemia. Cancer Discov. 11, 2868\u20132883. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1793 (2021).","journal-title":"Cancer Discov"},{"key":"21034_CR43","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41375-023-02108-3","volume":"38","author":"CE Birdwell","year":"2024","unstructured":"Birdwell, C. E. et al. Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression. Leukemia 38, 545\u2013556. https:\/\/doi.org\/10.1038\/s41375-023-02108-3 (2024).","journal-title":"Leukemia"},{"key":"21034_CR44","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1111\/bjh.19720","volume":"205","author":"M Nakamura","year":"2024","unstructured":"Nakamura, M. et al. Modelling and drug targeting of a myeloid neoplasm with atypical 3q26\/MECOM rearrangement using patient-specific iPSCs. Br. J. Haematol. 205, 1430\u20131443. https:\/\/doi.org\/10.1111\/bjh.19720 (2024).","journal-title":"Br. J. Haematol."},{"key":"21034_CR45","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/s43018-021-00177-w","volume":"2","author":"M Hashimoto","year":"2021","unstructured":"Hashimoto, M. et al. Combined Inhibition of XIAP and BCL2 drives maximal therapeutic efficacy in genetically diverse aggressive acute myeloid leukemia. Nat. Cancer. 2, 340\u2013356. https:\/\/doi.org\/10.1038\/s43018-021-00177-w (2021).","journal-title":"Nat. Cancer"},{"key":"21034_CR46","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/s41587-019-0201-4","volume":"37","author":"D Kim","year":"2019","unstructured":"Kim, D., Paggi, J. M., Park, C., Bennett, C. & Salzberg, S. L. Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat. Biotechnol. 37, 907\u2013915. https:\/\/doi.org\/10.1038\/s41587-019-0201-4 (2019).","journal-title":"Nat. Biotechnol."},{"key":"21034_CR47","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.1002\/imt2.107","volume":"2","author":"S Chen","year":"2023","unstructured":"Chen, S. Ultrafast one-pass FASTQ data preprocessing, quality control, and deduplication using Fastp. Imeta 2, e107. https:\/\/doi.org\/10.1002\/imt2.107 (2023).","journal-title":"Imeta"},{"key":"21034_CR48","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao, Y., Smyth, G. K. & Shi, W. FeatureCounts: An efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923\u2013930. https:\/\/doi.org\/10.1093\/bioinformatics\/btt656 (2014).","journal-title":"Bioinformatics"},{"key":"21034_CR49","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated Estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550. https:\/\/doi.org\/10.1186\/s13059-014-0550-8 (2014).","journal-title":"Genome Biol."},{"key":"21034_CR50","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/1471-2105-14-128","volume":"14","author":"EY Chen","year":"2013","unstructured":"Chen, E. Y. et al. Enrichr: Interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinform. 14, 128. https:\/\/doi.org\/10.1186\/1471-2105-14-128 (2013).","journal-title":"BMC Bioinform."},{"key":"21034_CR51","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov, M. V. et al. Enrichr: A comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 44, W90\u201397. https:\/\/doi.org\/10.1093\/nar\/gkw377 (2016).","journal-title":"Nucleic Acids Res."},{"key":"21034_CR52","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1002\/cpz1.90","volume":"1","author":"Z Xie","year":"2021","unstructured":"Xie, Z. et al. Gene set knowledge discovery with enrichr. Curr. Protoc. 1, e90. https:\/\/doi.org\/10.1002\/cpz1.90 (2021).","journal-title":"Curr. Protoc."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21034-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21034-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21034-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:02:20Z","timestamp":1761609740000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21034-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["21034"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-21034-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"assertion":[{"value":"31 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"D.I. has received prior research funding and venetoclax compounds from Abbvie. No other potential conflict of interest relevant to this article was reported. There are no competing interests of the other authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37099"}}